Developmental pharmacokinetics of opioids in neonates

Related Experiment Video

Updated: Jul 16, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

Karel Allegaert1, Sinno H Simons, Christine Vanhole

  • 1Division of Woman and Child, University Hospital, Gasthuisberg, Leuven, Belgium.

Journal of Opioid Management
|March 21, 2007
PubMed

Insights

Pain management in neonates requires a tailored approach. This study examines opioid pharmacokinetics in newborns, highlighting age-related changes and significant individual variations in drug metabolism.

Area of Science:

  • Neonatal pharmacokinetics
  • Developmental pharmacology
  • Pain management in neonates

Background:

  • Pain recognition and treatment are key indicators of neonatal care quality.
  • Population-specific characteristics necessitate tailored approaches to neonatal pain management.
  • Systematic pain assessment and safe analgesic administration are crucial for effective interventions.

Purpose of the Study:

  • To illustrate the impact of age on opioid pharmacokinetics and metabolism in neonates.
  • To examine tramadol disposition in early neonatal life.
  • To identify areas for future research in neonatal opioid pharmacokinetics.

Main Methods:

  • Utilizing recently collected and reported observations of tramadol disposition.
  • Analyzing age-dependent maturation of distribution volume and clearance.
  • Investigating interindividual variability in drug metabolism.

Main Results:

  • Age-dependent maturation of distribution volume and clearance was observed.
  • Significant and unexplained interindividual variability in drug metabolism persists.
  • Opioid pharmacokinetics and metabolism show considerable changes during neonatal development.

Conclusions:

  • Neonatal opioid pharmacokinetics are influenced by age and exhibit substantial interindividual variability.
  • Further research should focus on covariables affecting opioid pharmacokinetics/pharmacodynamics and long-term outcomes.
  • Optimizing neonatal pain management requires a deeper understanding of developmental drug disposition.

More Related Videos

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes05:13

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...